Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Taiwan University Hospital Hsin-Chu Branch | OTHER |
| Far Eastern Memorial Hospital | OTHER |
| National Taiwan University Hospital, Yun-Lin Branch | OTHER |
Not provided
Not provided
Not provided
This is a study to compare the treatment effect of different doses of ceftriaxone for gonorrhea.
This is a noninferiority randomized controlled trial to compare the treatment effect of 500-mg to 1000-mg of ceftriaxone for uncomplicated gonorrhea infection in men.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 500-mg ceftriaxone | Experimental | single-dose ceftriaxone 500-mg intramuscular injection, dissolved in 2 mL of 1% lidocaine hydrochloride solution |
|
| 1000-mg ceftriaxone | Active Comparator | single-dose ceftriaxone 1000-mg intramuscular injection, dissolved in 3.5 mL of 1% lidocaine hydrochloride solution |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ceftriaxone 500-mg | Drug | single-dose ceftriaxone 500-mg intramuscular injection, dissolved in 2 mL of 1% lidocaine hydrochloride solution |
|
| Measure | Description | Time Frame |
|---|---|---|
| Treatment response of UGI | The proportion of participants with successful treatment of UGI, defined as a NAAT-negative and, if applicable, a culture-negative result of the primary anatomic sites of infection 7-14 days after treatment; a culture-negative result is required only if N. gonorrhoeae culture was positive at the screening visit. | From enrollment to 14 days after treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Symptom duration | Symptom duration, including dysuria, genital discharge, sore throat, anorectal pain, rectal bleeding, and rectal discharge, in the subgroup of patients who have baseline symptoms attributable to UGIs. | From enrollment to 14 days after treatment |
| Treatment-related adverse events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Tzong-Yow Wu, M.D. | Contact | 886+933594074 | retep0102@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Taiwan University Hospital | Recruiting | Taipei | 100 | Taiwan |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Sep 30, 2025 | Jul 11, 2026 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D006069 | Gonorrhea |
| D012749 | Sexually Transmitted Diseases |
| ID | Term |
|---|---|
| D016870 | Neisseriaceae Infections |
| D016905 | Gram-Negative Bacterial Infections |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
Not provided
Not provided
| ID | Term |
|---|---|
| D002443 | Ceftriaxone |
| ID | Term |
|---|---|
| D002439 | Cefotaxime |
| D002505 | Cephacetrile |
| D002511 | Cephalosporins |
| D047090 | beta-Lactams |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ceftriaxone 1000-mg | Drug | single-dose ceftriaxone 1000-mg intramuscular injection, dissolved in 3.5 mL of 1% lidocaine hydrochloride solution |
|
Treatment-related adverse events until 14 days after treatment. |
| From enrollment to 14 days after treatment |
| MIC of ceftriaxone of isolates | MIC of ceftriaxone of isolates at screening and test-of-cure (TOC) visits. | From enrollment to 14 days after treatment |
| NG-MAST | NG-MAST at screening and TOC visits. | From enrollment to 14 days after treatment |
| Gene mutations associated with drug resistance for extended-spectrum cephalosporins | Gene mutations associated with drug resistance for extended-spectrum cephalosporins at screening and TOC visits. | From enrollment to 14 days after treatment |
| D007239 | Infections |
| D015231 | Sexually Transmitted Diseases, Bacterial |
| D003141 | Communicable Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007769 |
| Lactams |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D013843 | Thiazines |
| D013457 | Sulfur Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |